PMID- 16712664
OWN - NLM
STAT- MEDLINE
DCOM- 20060915
LR  - 20161128
IS  - 0300-0664 (Print)
IS  - 0300-0664 (Linking)
VI  - 64
IP  - 6
DP  - 2006 Jun
TI  - Peripheral fibrinolytic markers, soluble adhesion molecules, inflammatory 
      cytokines and endothelial function in hypopituitary adults with growth hormone 
      deficiency.
PG  - 632-9
AB  - BACKGROUND: Increased mortality due to cardiovascular disease has been described 
      in adult patients with untreated GH deficiency (GHD). GH replacement has been 
      demonstrate to improve vascular reactivity and reverse early atherosclerotic 
      changes in adults with GHD. OBJECTIVE: Assessment of fibrinolytic markers, 
      soluble adhesion molecules, inflammatory cytokines and endothelial function in 
      hypopituitary adults with GHD at baseline and 1 year after GH replacement 
      therapy. METHODS: We studied 10 patients with GHD (five men and five women; aged 
      45.6 +/- 10.4 years) at baseline and 1 year after GH replacement therapy compared 
      with a control group (nine men and 16 women) matched for age and body mass index 
      (BMI). All subjects, patients and controls, were life-long nonsmokers, 
      normotensive and nondiabetic. The following variables were recorded: 
      anthropometric and body composition variables, serum concentrations of glucose, 
      insulin and C-peptide; thrombin anti-thrombin (TAT) fragments and fibrin 
      degradation product D-dimer, which were determined by an enzyme-linked 
      immunosorbent assay (ELISA); IGF-I by radioimmunoassay (RIA); C-reactive protein 
      (CRP) by highly sensitive immunonephelometry; E-selectin, P-selectin, soluble 
      intercellular cell adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion 
      molecule-1 (sVCAM-1), interleukin-6 (IL-6) and monocyte chemoattractant protein-1 
      (MCP-1) by ELISA. The assessment of endothelial function in vivo was measured 
      with a Doppler device. RESULTS: Patients with GHD without GH substitution had 
      higher hip/waist ratio and body fat than controls. Insulin, C-peptide and 
      triglyceride concentrations were also higher. Our results demonstrated no 
      difference in fibrinogen and in TAT fragment concentrations among patients and 
      controls. E-selectin concentrations were higher in patients than in controls 
      (26.1 +/- 11 vs. 10.7 +/- 6.2 microg/l, P = 0.0001). P-selectin, sICAM-1, 
      sVCAM-1, IL-6, MCP-1 and CRP were similar in the two groups. Vascular reactivity 
      and carotid intima-media thickness (IMT) were also similar in patients and 
      controls. After 1 year of GH treatment we found no changes in biochemical 
      parameters, fibrinolytic markers, soluble adhesion molecules, inflammatory 
      cytokines and endothelial function. CONCLUSION: Adults with GHD show some subtle 
      changes in soluble adhesion molecules but our data suggest no beneficial effects 
      of GH over these markers in relationship to endothelial function. Factors other 
      than GH treatment, such as differences in age, degree of obesity, the presence of 
      diabetes mellitus and arterial hypertension or tobacco consumption, could explain 
      the observed increase in markers of vascular risk in GH-deficient patients.
FAU - Gomez, Jose Manuel
AU  - Gomez JM
AD  - Servicio de Endocrinologia y Nutricion, Hospital de la Santa Creu i Sant Pau, 
      Barcelona, Spain. jmgs@csub.scs.es
FAU - Sahun, Manel
AU  - Sahun M
FAU - Vila, Ramon
AU  - Vila R
FAU - Domenech, Pere
AU  - Domenech P
FAU - Catalina, Pablo
AU  - Catalina P
FAU - Soler, Juan
AU  - Soler J
FAU - Badimon, Lina
AU  - Badimon L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Endocrinol (Oxf)
JT  - Clinical endocrinology
JID - 0346653
RN  - 0 (Biomarkers)
RN  - 9002-72-6 (Growth Hormone)
SB  - IM
MH  - Adult
MH  - Analysis of Variance
MH  - Biomarkers/analysis/blood
MH  - Body Composition
MH  - Body Mass Index
MH  - Brachial Artery/diagnostic imaging
MH  - Case-Control Studies
MH  - Endothelium, Vascular/physiopathology
MH  - Female
MH  - Fibrinolysis/drug effects
MH  - Growth Hormone/*deficiency/therapeutic use
MH  - *Hormone Replacement Therapy
MH  - Humans
MH  - Hypopituitarism/drug therapy/*metabolism/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Regional Blood Flow
MH  - Time Factors
MH  - Ultrasonography
EDAT- 2006/05/23 09:00
MHDA- 2006/09/16 09:00
CRDT- 2006/05/23 09:00
PHST- 2006/05/23 09:00 [pubmed]
PHST- 2006/09/16 09:00 [medline]
PHST- 2006/05/23 09:00 [entrez]
AID - CEN2518 [pii]
AID - 10.1111/j.1365-2265.2006.02518.x [doi]
PST - ppublish
SO  - Clin Endocrinol (Oxf). 2006 Jun;64(6):632-9. doi: 
      10.1111/j.1365-2265.2006.02518.x.